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Objectives: In this study, the in vitro mammalian chromosomal aberration (CA) assay was conducted to gain additional informa-
tion concerning the hazards associated with the use of cyclopentane and ammonium nitrate. While these two chemicals had al-
ready been tested by many methods, they had not been studied in the CA test. 
Methods: The assay was performed using the ovarian infantile cell (CHO-K1 cell), by the direct method (-S9) and by the meta-
bolic activated method (+S9 mix). 
Results: Using the direct method, the 7 dosages in a 48 hour treatment group did not show that the frequency of CA is propor-
tion to the dosage addition. The frequency of CA is not proportion to the dosage addition for a 6 hour treatment using the meta-
bolic activated method. 
Conclusion: From these fi ndings, it was decided that the 2 chemicals do not induce chromosomal aberrations under the tested 
conditions.
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Introduction
The necessity for hazard assessment has increased, because the 
frequency of chemical exposure for workers is increasing as the 
chemical industries have been developed. Many chemicals that 
are used in industry represent current concerns since they may 
pose genetic hazards for humans. Since these substances are 
not limited to the original products, they have become wide-
spread as environmental pollutants, thus leading to concerns 
about a variety of chemicals that possibly threaten the health 
of  workers. In this respect, the regulation and evaluation of 
chemical hazards are important to human health and the work-
ing environment.
This study was conducted because insufficient informa-
tion was available about the potential hazards of cyclopentane 
(CAS No. 287-92-3) and ammonium nitrate (CAS No. 6484-
52-2), therefore an in vitro mammalian chromosomal aberra-
tion assay was performed to include in a hazard assessment. 
Moreover, toxicology information from this study can be used 
for a worker’s “right to know,” and to prepare or update the 
Materials Safety Data Sheet (MSDS) in many chemical indus-
tries.
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Cyclopentane is a central nervous system depressant in 
humans. Because the industrial use of  pure cyclopentane is 
limited and the commercial reagents and solvents that con-
tain cyclopentane also contain other hydrocarbons, there are 
few toxicological data on the effects of  exposure to the pure 
substance [1]. Exposure to cyclopentane can occur through 
inhalation, ingestion, and eye or skin contact. Cyclopentane 
is a central nervous system depressant in animals and applica-
tion of cyclopentane to the skin of guinea pigs caused redness 
and dryness [2]. The minimal narcotic concentration of cyclo-
pentane in mice is 38.3 ppm; this level of  exposure may also 
cause loss of  reflexes and death. Exposure to a cyclopentane 
concentration of 112 to 1,139 ppm for 6 hours/day for 3 weeks 
caused no effects in male and female rats; however, exposure to 
8,110 ppm for 6 hours/day for 12 weeks caused a decrease in 
the rate of body weight gain in female rats. The threshold limit 
value for cyclopentane in the workplace (TWA) is 600 ppm [1]. 
Cyclopentane produced a slight erythema on the skin but no 
additional affects were reported in male and female rats. 
Exposure of female rats to 8,110 ppm for 12 weeks (6 h/
day) led to decreased body weight gain [2] and also caused a 
skin dry appearance, thickening of skin, and affected arginase 
activity in the epidermis. A slight increase in the excretion of 
β-microglobulin was observed, indicating minor tubulotoxicity 
[3]. It was also reported to be a weak sensitizer of  the myo-
cardium to the effects of  adrenaline [4]. Symptoms of  acute 
exposure to high concentrations of cyclopentane include excite-
ment, loss of equilibrium, stupor, coma, and rarely, respiratory 
failure [5].
Cyclopentane has been detected in the blood of  chemi-
cally-sensitive patients, as analyzed by chromatography-mass 
spectrometry (GC-MS) [6,7]. In a Danish study conducted to 
delineate risks due to exposure of humans to neurotoxic chemi-
cals, cyclopentane has been assigned a risk index value of 2 on 
a 0 to 5 scale, i.e. “Chemicals with a small risk of damaging the 
nervous system during normal work with the substances” [8].
Occupational exposures to gasoline and petroleum prod-
ucts, including cyclopentane, were measured in numerous 
petroleum companies. Results of  long-term samples (n = 79) 
were: median value of  cyclopentane was 0.19 mg/m3, maxi-
mum 3.74 mg/m3, short-term samples (n = 105): median value 
of cyclopentane was 0.66 mg/m3, maximum 73.36 mg/m3 [9].
Ammonium nitrate (CAS No. 6484-52-2) uses include: 
a fertilizer in the agricultural industry, use in basic chemical 
synthesis, personal and domestic use, use as an oxidizing agent 
in the chemical industry and in the production of pharmaceuti-
cal drugs, etc. Exposures can occur when handling and using 
chemicals on farms. Occupational exposure of  workers, ap-
plicators, distributors, merchants and farm workers can occur 
during the manual handling of solid fertilizer products, or may 
occur by inhalation. The Good Laboratory Practice (GLP) 
reports the acute oral LD50 values as 2,085 mg/kg in mice and 
2,217 mg/kg in rats. Ellen et al. [10] administered single oral 
doses (0.15 g NH4NO3/kg) to 12 adult human volunteers with 
no measurable hematological effects, elevation of methaemo-
globin or detection of circulating N-nitroso-compounds. One 
subject developed diarrhea after 7 hrs and one vomited after 12 
minutes. Twelve other subjects, administered 9.5 g NaNO3 in 
750 mL water intravenously over a 1 hour period, showed no 
effects from the treatment.
Results from genotoxic evaluation, show that cyclopen-
tane is negative for activity in the Ames assay with Salmonella 
[11] and ammonium nitrate is negative for activity in the mi-
cronucleus test [12].
The identification of  toxicity that may pose a genetic 
hazard in our environment and workplace is currently of great 
importance [13], because there are many new chemicals used 
in chemical industry. Several assay systems demonstrating 
rapidity and reliability have been introduced for this purpose, 
such as the reversion test using bacterial gene mutation [14,15], 
chromosomal aberration assay using mammalian cells [16] and 
micronucleus assay using rodents [17,18].
It has been assumed that mutation represents at least one 
step in the mechanism of  carcinogenesis. The evidence sup-
porting this idea is that the majority of mutagens are carcino-
gens [19], and for at least some compounds, mutagenic potency 
is closely correlated with carcinogenic potency [20]. Moreover, 
mutagens and certain non-mutagenic carcinogens have also 
been found to induce chromosomal rearrangement [21] which 
may affect carcinogenesis by altering gene expression, perhaps 
by allowing the activation or inactivation of  cellular cancer 
genes [22].
In addition, -5,000 tons of  cyclopentane are used every 
year by -2,700 workers, and -32,000 tons of ammonium nitrate 
are used by -34,000 workers in Korea. It is necessary to assess 
these chemicals’ hazards, because worker exposure frequency is 
increasing and there are great concerns about genetic hazards.
The chromosomal aberration assay, conducted using 
mammalian cells, is frequently used to evaluate the genotoxic-
ity of chemicals and has been adopted as an index of genotox-
icity worldwide. Furthermore, it is utilized as a screening probe 
for the detection of possible carcinogenic substances. Despite 
its increasing use, the available genotoxicity data for cyclopen-
tane and ammonium nitrate are still controversial. Therefore, 
we evaluated their genotoxicity using the in vitro mammalian 
chromosomal aberration assay.
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Several short term methods have been developed for pre-
dicting the carcinogenicity of  chemicals and have also been 
introduced for the evaluation of genotoxicity [23,24] and anti-
mutagenicity [25]. Cytogenetic studies on mammalian cells 
in vivo [26,27] and in vitro [23] have also been widely used as 
screening methods to identify DNA-attacking substances.
We used CHO cells in this experiment because it has been 
reported that there are no sensitivity differences between CHO 
and Chinese hamster lung (CHL) cells in the vitro chromo-
some aberration assay [28,29].
 
Materials and Methods
Cells and chemicals
The cultivated CHO-K1 (Chinese hamster ovary fibroblast) 
cells used in this test were obtained from the Korean Cell Line 
Bank (KCLB 10061). Cells were cultured in F-12 medium 
(GIBCO BRL, NY, USA, Lot No. 507762) with 5% CO2 at 
37 oC, and sub-cultured every 2-4 days.
Ethanol (Merck, NJ, USA, Lot No. K35091883538) was 
used as a negative control for cyclopentane (Sigma, MO, USA, 
95%, Lot No. 10120721), and distilled water for ammonium 
nitrate (Sigma, MO, USA, > 99.5%, Lot No. 03416JH) and as 
a solvent according to results of a solubility test. 
Mitomycin C (MMC) (Sigma, MO, USA, Lot No. 
028K1815) and cyclophosphamide (CPA) (Sigma, MO, USA, 
Lot No. 076K1050) were used as positive controls in the study. 
For the metabolic activated system, the S9 (MOLTOXTM, An-
napolis, Maryland, USA, Lot No. 2374) was used within 6 
months after manufacture.
In vitro mammalian chromosomal aberration test
This study was performed according to OECD guidelines for 
the testing of chemicals (OECD, 1997) (In vitro Mammalian 
Chromosomal Aberration Test. Ref. OECD TG473) and Ishi-
date’s report [30].
For the cell proliferation suppression test, 7 dosages of 
each chemical (0.003, 0.007, 0.01, 0.03, 0.06, 0.125 and 0.25 
mM cyclopentane), and (0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 
10 mM ammonium nitrate) were use, respectively. For the 
direct method (24 and 48 hour treatment), the CHO-K1 cells 
were cultured for -3 days from an aliquot of 2 × 104- 4 × 104 
cells, in a 60 mm diameter plate. For the metabolic activated 
method (6 hour treatment), the cells were cultured using condi-
tions identical to the direct method. Slides for observation of 
chromosomal samples were made from 5 mL media aliquots, 
with 18 hour supplementary culture, after removal of  media 
and washing of the cell layer with 5 mL fresh media.
The main test was performed using dosages established 
by the cell proliferation suppression / preliminary test. After 24 
and 48 hours of exposure to test chemicals, plates were treated 
with 0.2 μg/mL Colcemid® (GIBCO BRL, NY, USA, Lot No. 
453240) After 2 hours, the metaphase cells were separated and 
centrifuged at 1,000 rpm for 5 min.
The chromosome samples were produced by fixing (3×) 
with the Carnoy's solution (acetic acid : ethanol = 1 : 3) and 
abnormalities were counted after 5 min of  staining with 5% 
Giemsa solution (Merck, NJ, USA, Lot No. HX888942). Two 
samples were made from each plate.
Two hundred metaphase cells were observed per plate and 
classified according to structural abnormalities (gap of  chro-
matid or chromosome;g, cutting of  chromatid;ctb, exchange 
of  chromatid;cte, cutting of  chromosome;csb, exchange of 
chromosome;cse and others) and numerical abnormalities (pol). 
Statistical analysis of the results was not performed.
Results were evaluated as “positive” only when the per-
centage of chromosomal aberrations was > 10%.
 
Results
Test for suppression of cell proliferation
The ratios of cell proliferation for the dosages of cyclopentane 
were 86.31% and 87.29% at 0.003 mM and 0.06 mM respec-
tively, for a 24 hour treatment using the direct method. More-
over cell proliferation ratios were 66.78%, 68.45%, 65.93%, 
55.55% and 51.03% at 0.003 mM, 0.01 mM, 0.06 mM, 0.125 
mM and 0.25 mM respectively, for a 48 hour treatment. For the 
direct method, it was conformed to the guideline of GLP [31] 
that the maximum concentration is over 5 mg/ml in case of the 
cellular toxicity not being recognized. 
Cell proliferation ratios were 89.90%, 64.74% at 0.007 
mM and 0.25 mM for a 6 hour treatment using the metabolic 
activated method. However, ammonium nitrate showed no 
suppression of cell proliferation after 24 hours of treatment us-
ing the direct method (89.40-240.26% at each concentration), 
and it was also conformed to the guideline of GLP [31] to de-
cide the maximum concentration.
Chromosomal aberration test
Duplicate samples of 100 cells per plate were observed in meta-
phase and classified for structural abnormalities (gap of chro-
matid or chromosome;g, cutting of  chromatid;ctb, exchange 
of  chromatid;cte, cutting of  chromosome;csb, exchange of 
chromosome;cse, etc) and numerical abnormalities (pol). Re-
sults were evaluated as being positive only when the percentage 
of chromosomal aberrations was ≥ 10% (≥ 20 abnormalities in 
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200 cells observed). A statistical analysis of the results was not 
performed.
The ratios of  chromosomal aberration using the direct 
method are shown in Tables 1-3 and 4. No diploid presence 
was observed at any concentration after 24 hour treatment. The 
structural chromosomal aberrations were < 5.0% in both with-
out gap (-gap) and with gap (+gap) groups. No dependency 
between chromosomal aberrations and dosages was observed.
Table 1. Chromosomal aberration test (direct method, 24 hr treatment) with cyclopentane
Treatment
Time of 
treatment 
(hr)
Conc. of 
treatment 
(mM)
Obs. Cell 
No.
No. of 
diploid
No. of chromosomal structure abnormality
DecisionGap Chromatid Chromosome
Etc.
Total
g ctb cte csb cse -g +g
Control solvent
  (Ethanol)
24 0 200 0   0   0 0 0 0 0 0 0 -
Test material 24   0.003 200 0   0 0 0 0 0 0 0 0 -
  0.007 200 0   0 0 0 0    0.5 0    0.5    0.5 -
0.01 200 0   0 0 0 0 0 0 0 0 -
0.03 200 0   0 0 0 0 0 0 0 0 -
0.06 200 0   0 0 0 0 0 0 0 0 -
  0.125 200 0   0 0 0 0 0 0 0 0 -
0.25 200 0   0 0 0 0 0 0 0 0 -
Positive control 
  (MMC)
24 0.0004 (mg/mL) 200 0 13 7  47.5 0    0.5    0.5  55.5  68.5 +
Conc.: concentration, Obs.: observed, No.: number, g: gap, ctb: chromatid break, cte: chromatid exchange, csb: chromosome break, cse: 
chromosome exchange, MMC: mitomycin C.
-: negative, +: positive, -g: without gap, +g: with gap.
Table 2. Chromosomal aberration test (direct method, 48 hr treatment) with cyclopentane
Treatment
Time of 
treatment 
(hr)
Conc. of 
treatment 
(mM)
Obs. cell 
No.
No. of 
diploid
No. of chromosomal structure abnormality
DecisionGap Chromatid Chromosome
Etc.
Total
g ctb cte csb cse -g +g
Control solvent
  (Ethanol)
48 0 200 0 0 0 0 0 0 0 0 0 -
Test material 48   0.003 200 0 0 0 0 0 0 0 0 0 -
  0.007 200 0 0   0.5 0 0 0 0   0.5   0.5 -
0.01 200 0 0 0 0 0 0 0 0 0 -
0.03 200 0 0 0 0 0 0 0 0 0 -
0.06 200 0 0 0 0 0 0 0 0 0 -
  0.125 200 0 0 0 0 0 0 0 0 0 -
0.25 200 0 0 0 0 0 0 0 0 0 -
Positive control
  (MMC)
48 0.0004 (mg/mL) 200 0 16.5   22 31.5 0 0 0 53.5   70 +
Conc.: concentration, Obs.: observed, No.: number, g: gap, ctb: chromatid break, cte: chromatid exchange, csb: chromosome break, cse: 
chromosome exchange, MMC: mitomycin C.
-: negative, +: positive, -g: without gap, +g: with gap.
Chromosomal Aberration Assay of Cyclopentane and Ammonium Nitrate
Saf Health Work 2011;2:17-25
21
www.e-shaw.org
The ratios of chromosomal aberration using the metabolic 
activated method are shown in Tables 5 and 6. All results were 
the same as from the direct method. It was shown that the two 
chemicals do not induce any chromosomal aberrations, using 
either the direct method (24 hour and 48 hour treatment or the 
metabolic activated method, (6 hour treatment) in CHO-K1 cells.
Table 3. Chromosomal aberration test (direct method, 24 hr treatment) with ammonium nitrate
Treatment
Time of 
treatment 
(hr)
Conc. of 
treatment 
(mM)
Obs. 
cell No.
No. of 
diploid
No. of chromosomal structure abnormality
DecisionGap Chromatid Chromosome
Etc.
Total
g ctb cte csb cse -g +g
Control solvent (DW) 24 0 200 0    0.5 0 0 0 0 0 0    0.5 -
Test material 24 0.156 200 0 0 0 0 0 0 0 0 0 -
0.313 200 0 1 0 0 0 0 0 0 1 -
0.625 200 0 0 0 0 0 0 0 0 0 -
1.25 200 0 0 0 0 0    0.5 0   0.5    0.5 -
2.5 200 0 0 0 0 0 1 0 1 1 -
5 200 0 2 0 0 0 0 0 0 2 -
10 200 0    0.5 0 0 0 0 0 0    0.5 -
Positive control 
(MMC)
24 0.0004 (mg/mL) 200 0 18.5 14  32.5 1  4.5 0 5 70.5 +
Conc.: concentration, Obs.: observed, No.: number, g: gap, ctb: chromatid break, cte: chromatid exchange, csb: chromosome break, cse: 
chromosome exchange, DW: distilled water, MMC: mitomycin C.
-: negative, +: positive, -g: without gap, +g: with gap.
Table 4. Chromosomal aberration test (direct method, 48 hr treatment) with ammonium nitrate
Treatment
Time of 
treatment 
(hr)
Conc. of 
treatment 
(mM)
Obs. 
cell No.
No. of 
diploid
No. and ratio of chromosomal structure abnormality
DecisionGap Chromatid Chromosome
Etc.
Total
g ctb cte csb cse -g +g
Control solvent (DW) 48 0 200 0 0 0 0 0 0 0 0 0 -
Test material 48 0.156 200 0 0 0 0 0 0 0 0 0 -
0.3125 200 0 0    0.5 0 0 0 0 0    0.5 -
0.625 200 0 0 1    1.5 0 0 0    2.5    2.5 -
1.25 200 0 0 0 0 0 0 0 0 0 -
2.5 200 0 0 0    0.5 0 0 0    0.5    0.5 -
5 200    0.5    0.5 0    0.5 0 0 0    0.5 1 -
10 200 0 0 0 0 0 0 0 0 0 -
Positive control 
  (MMC)
48 0.0004 (mg/mL) 200 0 20.5 19 28.5 0 0 0 47.5 68 +
Conc.: concentration, Obs.: observed, No.: number, g: gap, ctb: chromatid break, cte: chromatid exchange, csb: chromosome break, cse: 
chromosome exchange, DW: distilled water, MMC: mitomycin C.
-: negative, +: positive, -g: without gap, +g: with gap.
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Discussion
Chromosomal aberrations alter genomic sequence, and are 
mutagenic. More importantly, chromosomal aberrations may 
result in loss of  tumor suppressor genes and/or activation of 
oncogenes. Chromosomal aberrations occur quantitatively at 
Table 6. Chromosomal aberration test (metabolic activated method, 6 hr treatment) with ammonium nitrate
Treatment
Time of 
treatment 
(ht)
Conc. of 
treatment 
(mM)
Obs. cell 
No.
No. of 
diploid
No. and ratio of chromosomal structure abnormality
DecisionGap Chromatid Chromosome
Etc.
Total
g ctb cte csb cse -g +g
Control solvent
  (DW)
24 (6+18) 0 200 0 0 0    0.5 0 0 0 0.5 0.5 -
Test material 24 (6+18) 0.156 200 0 0 0 0 0    0.5 0 0.5 0.5 -
0.3125 200 0 0 0    0.5 0 0 0 0.5 0.5 -
0.625 200 0 0 0 0 0 0 0 0 0 -
1.25 200 0    0.5 0 0 0 0 0 0 0.5 -
2.5 200 0    0.5 0    0.5    0.5 0 0 1 1.5 -
5 200 0    1.5 0 0 0    0.5 0 0.5 2 -
10 200 0 0    0.5 0 0 0 0 0.5 0.5 -
Positive control
  (CPA)
24 (6+18) 0.01 (mg/ml) 200 0    9.5    9.5  32.5 0 0 0  42 51.5 +
Conc.: concentration, Obs.: observed, No.: number, g: gap, ctb: chromatid break, cte: chromatid exchange, csb: chromosome break, cse: 
chromosome exchange, DW: distilled water, CPA: cyclophosphamide.
-: negative, +: positive, -g: without gap, +g: with gap.
Table 5. Chromosomal aberration test (metabolic activated method, 6 hr treatment) with cyclopentane
Treatment
Time of 
treatment 
(ht)
Conc. of 
treatment 
(mM)
Obs. 
cell No.
No. of 
diploid
No. of chromosomal structure abnormality
DecisionGap Chromatid Chromosome
Etc.
Total
g ctb cte csb cse -g +g
Control solvent 
  (Ethanol)
24 (6 +18)         0 200 0 0 0 0 0 0.5 0 0.5 0.5 -
Test material 24 (6 +18)   0.003 200 0 0 0 0 0 0 0 0 0 -
  0.007 200 0 0 0 0 0 0 0 0 0 -
0.01 200 0 0 0 0 0 0 0 0 0 -
0.03 200 0 0 0 0 0 0 0 0 0 -
0.06 200 0 0 0 0 0 0 0 0 0 -
  0.125 200 0 0 0 0 0 0 0 0 0 -
0.25 200 0 0 0     0.5 0 0 0    0.5    0.5 -
Positive control
  (CPA)
24 (6 +18) 0.01 (mg/mL) 200 0    9.5  11.5 78 0 0 0 50.5 60 +
Conc.: concentration, Obs.: observed, No.: number, g: gap, ctb: chromatid break, cte: chromatid exchange, csb: chromosome break, cse: 
chromosome exchange, CPA: cyclophosphamide .
-: negative, +: positive, -g: without gap, +g: with gap.
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a much smaller scale compared to DNA sequence mutations, 
however, their biological consequences are generally more se-
vere than most point mutations [32].
From this study, cyclopentane and ammonium nitrate did 
not induce chromosomal aberrations using either the direct 
method (24 hours and 48 hours treatment) or the metabolism 
activated method, (6 hour test treatment) with CHO-K1 cells.
The purpose of the in vitro chromosomal aberration test 
is to identify agents that cause structural chromosome aberra-
tions in cultured mammalian cells [33]. Structural aberrations 
may be of two types, chromosome or chromatid. For the ma-
jority of  chemical mutagens, induced aberrations are of  the 
chromatid type, but chromosomal-type aberrations also occur. 
An increase in polyploidy may indicate that a chemical has the 
potential to induce numerical aberrations. Chromosome muta-
tions and related events are the cause of many human genetic 
diseases and there is substantial evidence that chromosome 
mutations and related events cause alterations in oncogenes 
and tumor suppressor genes of somatic cells which are involved 
in cancer induction in humans and experimental animals [33].
Tests conducted in vitro generally require the use of an ex-
ogenous source of metabolic activation. This metabolic activa-
tion system cannot entirely mimic the mammalian in vivo con-
ditions. Care should be taken to avoid conditions that would 
lead to positive results, but do not reflect intrinsic mutagenicity, 
and may arise from changes in pH, osmolarity or high levels of 
cytotoxicity [34,35].
The frequency of  chromosomal aberrations (CAs) in 
peripheral blood lymphocytes has been applied for decades as 
a biomarker for the early effects of  genotoxic carcinogens in 
occupational and environmental settings (including biodosim-
etry of radiation) [36,37]. CAs in lymphocytes are thought to 
represent a surrogate endpoint for more specific chromosome 
alterations in target tissues of  carcinogenesis. Assuming that 
the mechanisms of chromosome damage formation are similar 
in different tissues, the level of damage in lymphocytes can be 
expected to reflect the level of damage in cancer-prone tissues 
and to indicate cancer risk [38,39].
An association between high CA frequency and increased 
cancer incidence was originally detected by the Nordic Study 
Group on the Health Risk of Chromosome Damage in a col-
laborative project of  10 Nordic cytogenetic laboratories [40]. 
An independent study among 10 laboratories from Italy, based 
on cancer mortality data, also concluded that CA is predictive 
of  cancer risk. The Nordic and Italian cohorts were subse-
quently combined by the European Study Group on Cytoge-
netic Biomarkers and Health for an updated analysis, which 
confirmed the cancer risk prediction of  CA frequency, but 
suggested no such association for SCEs or MN [41-43]. Both 
chromatid-type and chromosome-type CAs were predictive of 
cancer risk. However, there is some evidence that chromosome-
type CAs may have better predictive value than chromatid-type 
CAs. SCEs do not appear to be indicative of cancer risk [44-47].
Moreover, how these toxic chemicals behave inside the or-
ganism is one of the big issues that needs to be resolved. These 
toxic chemicals can trigger stress reactions that lead to inflam-
mation and weaken the body’s defense against other pathogens. 
Some chemicals accumulate in organs; another concern is their 
potential interaction with biological pathways inside the body, 
which may affect the regulatory mechanisms of enzymes and 
other proteins. Many other chemicals have proved toxic to 
human tissue and cell cultures, by producing increased oxida-
tive stress, inflammatory cytokine production and cell death. 
Studies have demonstrated the potential for chemicals to cause 
DNA mutation and resulting cell death. Internal phenomena 
such as metabolism, errors of  DNA replication, inflamma-
tion, and oxidative stress may be of importance. Inflammatory 
diseases, oxidative stress, and radiation exposure have been as-
sociated with the generation of clastogenic factors which may 
be quite persistent and might play an important role in carcino-
genesis and thereby, in the association between CAs and can-
cer. Furthermore, availability of micronutrients, such as folate, 
appears to be important for maintaining genome integrity [48].
The CA test is used to screen for possible mammalian 
mutagens and carcinogens. Many compounds that are positive 
in this test are mammalian carcinogens; however, there is not a 
perfect correlation between this test and carcinogenicity. Cor-
relation is dependent on chemical class and there is increasing 
evidence that there are carcinogens that are not detected by this 
test, because they appear to act through mechanisms other than 
direct DNA damage.
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